00000000nam 2200000za 4500
0019.833924
003CaOODSP
00520221107150324
007cr |||||||||||
008170427s2017    onc     ob   f000 0 eng d
020 |a978-0-660-08010-9
040 |aCaOODSP|beng
043 |an-cn---
0861 |aHP40-177/2017E-PDF
24500|aCanadian HIV Vaccine Initiative achievements report |h[electronic resource].
260 |aOttawa : |bPublic Health Agency of Canada, |c2017.
300 |ai, 29 p.
500 |aIssued also in French under title: Rapport des réalisations Initiative canadienne de vaccin contre le VIH.
500 |aCover title.
500 |a"Publication date: March 2017"--Verso of cover.
504 |aIncludes bibliographical references.
520 |a"The Canadian HIV Vaccine Initiative (CHVI), which concludes in March 2017, has been a unique collaboration between the Government of Canada (GoC) (the Public Health Agency of Canada (PHAC); Health Canada (HC); the Canadian Institutes of Health Research (CIHR); Innovation, Science and Economic Development (ISED); the National Research Council (NRC); and Global Affairs Canada (GAC)) and the Bill & Melinda Gates Foundation (BMGF) to further strengthen global efforts to accelerate the development of a safe, effective, affordable and globally accessible HIV vaccine. An investment of $139M (GoC - $111M from existing resources; BMGF - $28M) was made to support CHVI activities since 2007, a small investment considering that, in 2009, the total costs of HIV in Canada (loss of quality of life, health care costs, and productivity loss) was estimated at just over $4 billion. Overall, CHVI activities served to advance global research and development (R&D) on HIV vaccine research and other HIV-related research, and to increase the visibility of Canadian HIV vaccine research, both domestically and internationally … "--Executive summary, p. 1.
69207|2gccst|aAIDS (disease)
69207|2gccst|aImmunization
69207|2gccst|aResearch and development
7102 |aPublic Health Agency of Canada.
77508|tRapport des réalisations Initiative canadienne de vaccin contre le VIH |w(CaOODSP)9.833925
85640|qPDF|s351 KB|uhttps://publications.gc.ca/collections/collection_2017/aspc-phac/HP40-177-2017-eng.pdf
986 |a160352